Year-end Sale % OFF 
Abstract
Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway is extensively explored in cancers. It functions as an important regulator of cell growth, survival and metabolism. Activation of this pathway also predicts poor prognosis in numerous human malignancies. Drugs targeting this signaling pathway have been developed and have shown preliminary clinical activity. Accumulating evidence has highlighted the important role of PI3K in non-Hodgkin lymphoma (NHL), especially in the disease initiation and progression. Therapeutic functions of PI3K inhibitors in NHL have been demonstrated both in vivo and in vitro. This review will summarize recent advances in the activation of PI3K signaling in different types of NHL and the applications of PI3K inhibitors in NHL treatment.
Highlights
The Phosphatidylinositol 3-kinase (PI3K)/Akt/Mammalian target of rapamycin (mTOR) pathway plays a critical role in regulating cancer cell growth, survival, motility and metabolism [1]
As PI3K/Akt/mTOR pathway plays a key role in the proliferation and survival of lymphoma cell, various inhibitors targeting this pathway have been studied in different types of non-Hodgkin lymphoma (NHL) (Table 1)
The results showed that CAL-101 promoted Chronic lymphocytic leukemia (CLL) cells apoptosis in a dose- and time-dependent pattern
Summary
The PI3K/Akt/mTOR pathway plays a critical role in regulating cancer cell growth, survival, motility and metabolism [1]. As PI3K/Akt/mTOR pathway plays a key role in the proliferation and survival of lymphoma cell, various inhibitors targeting this pathway have been studied in different types of NHL (Table 1). NVP-BEZ235, a dual PI3K and mTOR inhibitor, was indicated to be effective in inhibiting FL cell proliferation [14].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
